ADMA Biologics (NASDAQ:ADMA) and Century Therapeutics (NASDAQ:IPSC) Critical Review

ADMA Biologics (NASDAQ:ADMAGet Rating) and Century Therapeutics (NASDAQ:IPSCGet Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Institutional & Insider Ownership

60.8% of ADMA Biologics shares are owned by institutional investors. Comparatively, 37.0% of Century Therapeutics shares are owned by institutional investors. 5.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 10.3% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares ADMA Biologics and Century Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ADMA Biologics $80.94 million 7.68 -$71.65 million ($0.37) -8.54
Century Therapeutics N/A N/A -$95.82 million ($1.97) -5.42

ADMA Biologics has higher revenue and earnings than Century Therapeutics. ADMA Biologics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for ADMA Biologics and Century Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADMA Biologics 0 0 2 0 3.00
Century Therapeutics 0 1 7 0 2.88

ADMA Biologics presently has a consensus price target of $5.00, indicating a potential upside of 58.23%. Century Therapeutics has a consensus price target of $25.33, indicating a potential upside of 137.20%. Given Century Therapeutics’ higher probable upside, analysts clearly believe Century Therapeutics is more favorable than ADMA Biologics.


This table compares ADMA Biologics and Century Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ADMA Biologics -53.89% -52.73% -21.55%
Century Therapeutics N/A -34.65% -25.09%

Volatility & Risk

ADMA Biologics has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Century Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.


ADMA Biologics beats Century Therapeutics on 7 of the 13 factors compared between the two stocks.

About ADMA Biologics

(Get Rating)

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

About Century Therapeutics

(Get Rating)

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with's FREE daily email newsletter.